Study of nucresiran for hereditary nerve condition (hATTR-PN)
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new medicine called nucresiran for people with a rare genetic nerve condition (hATTR-PN). The goal is to see if it can slow down or improve nerve damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with hereditary transthyretin amyloidosis that affects your nerves (hATTR-PN).
- Your nerve symptoms should fall within a moderate range on a doctor's exam (score of 5 to 130 on the neuropathy scale).
- You need to be able to do most daily activities on your own (KPS score of 60% or higher).
- You cannot have had a liver transplant, or be planning one soon.
- Your heart failure (if any) should be mild—no worse than Class II on the NYHA scale.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
This study is testing a new gene-silencing treatment called NTLA-2001 for people with hereditary ATTR amyloidosis that causes nerve damage. It works by stopping the body from making a faulty protein that builds up and harms nerves.
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
This trial tests whether the drug tafamidis can help people with a specific type of nerve damage caused by abnormal protein buildup. It aims to slow or improve symptoms in adults with this condition.
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Hear when a new Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.